Literature DB >> 15917638

Quantitating defective ribosome products.

Shu-Bing Qian1, Jack R Bennink, Jonathan W Yewdell.   

Abstract

The fidelity of the protein production process is monitored by quality control machinery, which ensures that aberrant proteins are not deployed throughout the cell. A significant fraction (upwards of 30%) of proteins are degraded by proteasomes shortly after their synthesis, and we have termed such proteins defective ribosomal proteins (DRiPs). It is of interest and importance to characterize qualitatively and quantitatively this cohort of rapidly degraded nascent proteins. Quantitating DRiPs entails employing a standard pulse-chase protocol using radiolabeled amino acids. Protein degradation kinetics can be determined by either acid precipitation or SDS-PAGE. The introduction of proteasome inhibitors enables quantitation of proteasome-mediated protein degradation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917638     DOI: 10.1385/1-59259-895-1:271

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Potential roles for ubiquitin and the proteasome during ribosome biogenesis.

Authors:  Diana A Stavreva; Miyuki Kawasaki; Miroslav Dundr; Karel Koberna; Waltraud G Müller; Teruko Tsujimura-Takahashi; Wataru Komatsu; Toshiya Hayano; Toshiaki Isobe; Ivan Raska; Tom Misteli; Nobuhiro Takahashi; James G McNally
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

2.  Ubiquitous Autofragmentation of Fluorescent Proteins Creates Abundant Defective Ribosomal Products (DRiPs) for Immunosurveillance.

Authors:  Jiajie Wei; James S Gibbs; Heather D Hickman; Stephanie S Cush; Jack R Bennink; Jonathan W Yewdell
Journal:  J Biol Chem       Date:  2015-05-13       Impact factor: 5.157

3.  Selective vulnerability of neurons to acute toxicity after proteasome inhibitor treatment: implications for oxidative stress and insolubility of newly synthesized proteins.

Authors:  Kalavathi Dasuri; Philip J Ebenezer; Le Zhang; Sun Ok Fernandez-Kim; Romina M Uranga; Elena Gavilán; Alessia Di Blasio; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2010-08-01       Impact factor: 7.376

4.  Flow Cytometry Analysis of HIV-1 Env Conformations at the Surface of Infected Cells and Virions: Role of Nef, CD4, and SERINC5.

Authors:  Isabelle Staropoli; Jérémy Dufloo; Olivier Schwartz; Nicoletta Casartelli; Anaïs Ducher; Pierre-Henri Commere; Anna Sartori-Rupp; Sophie Novault; Timothée Bruel; Valérie Lorin; Hugo Mouquet
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

5.  Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.

Authors:  Jiajie Wei; Damien Zanker; Anthony R Di Carluccio; Margery G Smelkinson; Kazuyo Takeda; Mina O Seedhom; Devin Dersh; James S Gibbs; Ning Yang; Ajit Jadhav; Weisan Chen; Jonathan W Yewdell
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

6.  A cotranslational ubiquitination pathway for quality control of misfolded proteins.

Authors:  Feng Wang; Larissa A Durfee; Jon M Huibregtse
Journal:  Mol Cell       Date:  2013-04-11       Impact factor: 17.970

7.  Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.

Authors:  Georg Gasteiger; Wolfgang Kastenmuller; Ronny Ljapoci; Gerd Sutter; Ingo Drexler
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

Review 8.  Antigen processing and presentation in HIV infection.

Authors:  Julie Boucau; Sylvie Le Gall
Journal:  Mol Immunol       Date:  2018-04-07       Impact factor: 4.407

9.  Premature translational termination products are rapidly degraded substrates for MHC class I presentation.

Authors:  Joshua R Lacsina; Odessa A Marks; Xiongfei Liu; David W Reid; Sujatha Jagannathan; Christopher V Nicchitta
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  Random amino acid mutations and protein misfolding lead to Shannon limit in sequence-structure communication.

Authors:  Andreas Martin Lisewski
Journal:  PLoS One       Date:  2008-09-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.